Development of Potent Inhibitors of proto-oncogene PELP1 for Treating Advanced Breast Cancer

开发用于治疗晚期乳腺癌的原癌基因 PELP1 强效抑制剂

基本信息

项目摘要

Project summary Breast cancer (BCa) is the second leading cause of cancer death in women. Among Servicewomen, BCa is the most commonly diagnosed cancer, accounting for 30% of female cancers with increased prevalence in older Veterans. BCa has distinct molecular subtypes; estrogen receptor (ER) positive and triple negative breast cancer (TNBC). A significant portion of ER-positive BCa initially respond to anti-estrogens or aromatase inhibitors but eventually exhibit unresponsiveness to therapy, develop therapy-resistant breast cancer (TR-BC), and ultimately progress to incurable metastasis. Moreover, TNBC has a more aggressive clinical course and overall lack of targeted therapies. Development of effective therapies for female Veterans with TR-BC or TNBC represents the highest unmet need in breast cancer treatment. Our ongoing research on PELP1, an oncogenic coregulator protein originally cloned in this lab, displays an integral role in multiple nuclear receptor (NR) functions associated with BCa progression. PELP1 expression is commonly dysregulated in BCa eliciting a conducive environment for epigenetic modifications. Concomitantly, PELP1 is a prognostic indicator for poorer BCa survival and indicator of therapy resistance and metastases. We have developed a first-in-class small molecule inhibitor of PELP1 (SMIP) displaying effectivity against TR-BC and TNBC. SMIPs block PELP1’s ability to promote epigenetic modifications. The objective of this proposal is to further develop a lead SMIP into a novel drug for the clinical treatment of TR-BC and TNBC. Our overarching hypothesis is that PELP1 couples NRs with epigenetic modifiers; therefore, targeting the PELP1 axis with SMIPs will have a therapeutic utility in treating both TR-BC and TNBC. In Aim 1, we will determine lead SMIPs mechanism of action using biochemical, molecular, unbiased mass spectroscopy, and whole genome sequencing approaches. In Aim 2, we will optimize SMIP derivatives and conduct studies establishing the maximum tolerated dose and dose efficacy in vivo using TR-BC and TNBC models. In Aim 3, we will test the translatability of optimized SMIPs using therapy resistant xenografts, metastatic models, and patient derived xenografts (PDX). This proposal is innovative as SMIPs block signaling from multiple oncogenic PELP1 activated NRs to uniquely promote repression of epigenetic modifiers. Successful completion of the proposed work will result in the development of a first-in-class cancer therapy drug specifically addressing the current lack of TR-BC and TNBC targeted therapies. This research program is significant as it is expected to aid in identifying therapeutic targets critical to the treatment and prevention of advanced breast cancer in the population of Servicewomen.
项目摘要 乳腺癌(BCa)是女性癌症死亡的第二大原因。在女军人中,BCa是 最常诊断的癌症,占女性癌症的30%,老年人的患病率增加 老兵BCa有不同的分子亚型;雌激素受体(ER)阳性和三阴性乳腺癌 癌症(TNBC)。很大一部分ER阳性BCa最初对抗雌激素或芳香化酶抑制剂有反应 但最终表现出对治疗的无反应性,发展为治疗抵抗性乳腺癌(TR-BC), 最终发展为无法治愈的转移。此外,TNBC具有更具侵略性的临床过程,并且总体而言, 缺乏针对性治疗。为患有TR-BC或TNBC的女性退伍军人开发有效疗法 这是乳腺癌治疗中最大的未满足需求。我们正在进行的关于PELP 1的研究, 辅助调节蛋白最初在本实验室克隆,在多核受体(NR)中发挥不可或缺的作用, 与BCa进展相关的功能。PELP 1表达通常在BCa中失调, 表观遗传修饰的有利环境。同时,PELP 1是一个预后指标, BCa存活率和治疗抗性和转移的指标。我们开发了一流的小型 PELP 1的分子抑制剂(SMIP)显示出对TR-BC和TNBC有效。SMIP阻止PELP 1的能力 来促进表观遗传修饰该提案的目的是进一步将领先的SMIP开发成一种新颖的 用于临床治疗TR-BC和TNBC的药物。我们的首要假设是PELP 1与NR结合 因此,用SMIP靶向PELP 1轴将具有治疗效用, TR-BC和TNBC。在目标1中,我们将使用生物化学, 分子、无偏质谱和全基因组测序方法。在目标2中,我们将优化 SMIP衍生物和进行研究,建立体内最大耐受剂量和剂量功效, TR-BC和TNBC模型。在目标3中,我们将使用治疗抗性测试优化的SMIP的可翻译性。 异种移植物、转移模型和患者来源的异种移植物(PDX)。这一建议是创新的SMIP块 来自多个致癌PELP 1激活的NR的信号传导以独特地促进表观遗传修饰物的抑制。 成功完成拟议的工作将导致开发一流的癌症治疗方法 药物专门解决目前缺乏TR-BC和TNBC靶向治疗。这项研究计划是 因为预期其有助于鉴定对治疗和预防以下疾病至关重要的治疗靶点, 晚期乳腺癌的发病率

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ratna K Vadlamudi其他文献

Ratna K Vadlamudi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ratna K Vadlamudi', 18)}}的其他基金

Development of Potent Inhibitors of proto-oncogene PELP1 for Treating Advanced Breast Cancer
开发用于治疗晚期乳腺癌的原癌基因 PELP1 强效抑制剂
  • 批准号:
    10412909
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
Development of Potent Inhibitors of proto-oncogene PELP1 for Treating Advanced Breast Cancer
开发用于治疗晚期乳腺癌的原癌基因 PELP1 强效抑制剂
  • 批准号:
    10516093
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
PELP1, a Novel Regulator of Estrogen Receptor
PELP1,一种新型雌激素受体调节剂
  • 批准号:
    7252323
  • 财政年份:
    2003
  • 资助金额:
    --
  • 项目类别:
PELP1, a Novel Regulator of Estrogen Receptor
PELP1,一种新型雌激素受体调节剂
  • 批准号:
    7119986
  • 财政年份:
    2003
  • 资助金额:
    --
  • 项目类别:
PELP1, a Novel Regulator of Estrogen Receptor
PELP1,一种新型雌激素受体调节剂
  • 批准号:
    8608682
  • 财政年份:
    2003
  • 资助金额:
    --
  • 项目类别:
PELP1, a Novel Regulator of Estrogen Receptor
PELP1,一种新型雌激素受体调节剂
  • 批准号:
    7209920
  • 财政年份:
    2003
  • 资助金额:
    --
  • 项目类别:
PELP1, a Novel Regulator of Estrogen Receptor
PELP1,一种新型雌激素受体调节剂
  • 批准号:
    8211872
  • 财政年份:
    2003
  • 资助金额:
    --
  • 项目类别:
PELP1, a Novel Regulator of Estrogen Receptor
PELP1,一种新型雌激素受体调节剂
  • 批准号:
    6933178
  • 财政年份:
    2003
  • 资助金额:
    --
  • 项目类别:
PELP1, a Novel Regulator of Estrogen Receptor
PELP1,一种新型雌激素受体调节剂
  • 批准号:
    6791280
  • 财政年份:
    2003
  • 资助金额:
    --
  • 项目类别:
PELP1, a Novel Regulator of Estrogen Receptor
PELP1,一种新型雌激素受体调节剂
  • 批准号:
    8530295
  • 财政年份:
    2003
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
  • 批准号:
    10100360
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Collaborative R&D
Accounting for the Fall of Silver? Western exchange banking practice, 1870-1910
白银下跌的原因是什么?
  • 批准号:
    24K04974
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
CPS: Medium: Making Every Drop Count: Accounting for Spatiotemporal Variability of Water Needs for Proactive Scheduling of Variable Rate Irrigation Systems
CPS:中:让每一滴水都发挥作用:考虑用水需求的时空变化,主动调度可变速率灌溉系统
  • 批准号:
    2312319
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Standard Grant
A New Direction in Accounting Education for IT Human Resources
IT人力资源会计教育的新方向
  • 批准号:
    23K01686
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An empirical and theoretical study of the double-accounting system in 19th-century American and British public utility companies
19世纪美国和英国公用事业公司双重会计制度的实证和理论研究
  • 批准号:
    23K01692
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An Empirical Analysis of the Value Effect: An Accounting Viewpoint
价值效应的实证分析:会计观点
  • 批准号:
    23K01695
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Accounting model for improving performance on the health and productivity management
提高健康和生产力管理绩效的会计模型
  • 批准号:
    23K01713
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
New Role of Not-for-Profit Entities and Their Accounting Standards to Be Unified
非营利实体的新角色及其会计准则将统一
  • 批准号:
    23K01715
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving Age- and Cause-Specific Under-Five Mortality Rates (ACSU5MR) by Systematically Accounting Measurement Errors to Inform Child Survival Decision Making in Low Income Countries
通过系统地核算测量误差来改善特定年龄和特定原因的五岁以下死亡率 (ACSU5MR),为低收入国家的儿童生存决策提供信息
  • 批准号:
    10585388
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了